Search Results
You are looking at 1 - 1 of 1 items for
- Author: J Guigay x
- Refine by access: All content x
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) chemotherapy in this population. A single-center retrospective analysis of consecutive G3-NEC patients treated with FOLFOX chemotherapy after failure of a cisplatinum-based regimen between December 2003 and June 2012 was performed. Progression-free survival (PFS), overall survival (OS), response rate, and safety were assessed according to RECIST 1.1 and NCI.CTC v4 criteria. Twenty consecutive patients were included (seven males and 13 females; median age 55; range 23–87 years) with a performance status of 0–1 in 75% of them. Primary location was gastroenteropancreatic in 12, thoracic in four, other in two, and unknown in two patients. There were 12 (65%) large-cell and 7 (30%) small-cell G3-NEC tumors, and 1 (5%) unknown. All patients had distant metastases. Twelve (60%) patients received FOLFOX as second-line treatment and 8 (40%) as third-line treatment or later and the median number of administered cycles was 6 (range 3–14). The median follow-up was 19 months. Median PFS was 4.5 months. Among the 17 evaluable patients, five partial responses (29%), six stable diseases (35%), and six progressive diseases (35%) were observed. Median OS was 9.9 months. Main Grade 3–4 toxicities were neutropenia (35%), thrombopenia (20%), nausea/vomiting (10%), anemia (10%), and elevated liver transaminases (10%). Our results indicate that the FOLFOX regimen could be considered as a second-line option in poorly differentiated G3-NEC patients after cisplatinum-based first-line treatment but warrant further confirmation in future larger prospective studies.